<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190242</url>
  </required_header>
  <id_info>
    <org_study_id>P050706</org_study_id>
    <nct_id>NCT00190242</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients</brief_title>
  <acronym>HEPAVAC</acronym>
  <official_title>Study of Immunogenicity of Anti-HAV Immunisation in HIV-1 Infected Patients, Co-infected or Not With HBV and/or HCV. HEP.A.VAC Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ensemble contre le SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunogenicity is reduced in immunocompromised patients. The aim of this prospective
      randomized study is to evaluate tolerance and immunogenicity of 2 doses versus 3 doses of
      anti-HAV vaccine in HIV-1 infected patients with CD4 count between 200 and 500 per mm3,
      co-infected or not with HBV and/or HCV. The factors influencing vaccine immunogenicity will
      be evaluate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RECOMMANDATIONS for hepatitis A vaccination is the same for HIV-infected patients than for
      general population. However, immunogenicity induced with 2 doses of anti-HAV vaccine is lower
      in HIV-infected patients. The primary objective of the study is to compare the immunogenicity
      (percentage of patients with anti-HAV antibodies &gt; 20 mUI/ml at month 7) of 2 strategies (2
      doses at months 1 and 6, versus 3 doses at months 1, 2 and 6)of anti-HAV vaccine in HIV-1
      infected patients co-infected with HBV and/or HCV with CD4 cell count between 200 and
      500/mm3. The second objectives are to compare mean anti-HAV antibodies titers obtained with
      the 2 strategies, the durability of the seroprotection 12 months after the end of
      vaccination, and the safety. The PARAMATERS than may have an effect on the immune response
      will be evaluated.

      This open, prospective, study have included 99 patients, aged from 18 to 55 years old.
      Patients were randomized to receive 2 or 3 doses of HAVRIX 1440 UI intramuscularly at week O,
      4, and 24 or week 0, and 24. Clinical and biological safety is evaluated after each
      immunisation and blood samples for serological evaluation taken at week -4, 4, 8, 24 and 28
      for immunogenicity and week 72 for long term analysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percentage of patients with anti-HAV antibodies superior 20 mUI/ml 7 months after the first vaccination</measure>
    <time_frame>during de study</time_frame>
    <description>percentage of patients with anti-HAV antibodies superior 20 mUI/ml 7 months after the first vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anti-HAV antibodies mean geometric titers 7 months after the first vaccination</measure>
    <time_frame>during the study</time_frame>
    <description>anti-HAV antibodies mean geometric titers 7 months after the first vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>durability of seroprotection 1 year after the end of vaccination</measure>
    <time_frame>during the study</time_frame>
    <description>durability of seroprotection 1 year after the end of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>during the study</time_frame>
    <description>safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>predictive factors of vaccinal response</measure>
    <time_frame>during the study</time_frame>
    <description>predictive factors of vaccinal response</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>group1:3 administrations of Havrix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group 1 received immunisation with Havrix (1440IU) at weeks S0, S4, S24</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group2: 2 administrations of Havrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group 2 received usual immunisation with Havrix (1440IU) at weeks S0 and S24</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group1</intervention_name>
    <description>Havrix at 1440IU was administrated à weeks S0, S4 and S24</description>
    <arm_group_label>group1:3 administrations of Havrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>group2</intervention_name>
    <description>Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS</description>
    <arm_group_label>group2: 2 administrations of Havrix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  VIH-1 infection, aged 18-55 years negative anti-HAV IgG CD4 cell count between 200 and
             500/mm3

        Exclusion Criteria:

          -  prior anti-HAV vaccination immunosuppressive treatment splenectomy Prothrombin time &lt;
             50%, platelets&lt; 50 000/mm3 fever serum alanine aminotransferase (ALT) or aspartate
             aminotransferase (AST) activity &gt; 2 ULN for non co-infected patients, &gt; 5 ULN for
             co-infected patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Odile Launay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie GRABAR, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC de vaccinologie Cochin Pasteur, Service de médecine interne, hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CISIH, Hôpital de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>December 15, 2011</last_update_submitted>
  <last_update_submitted_qc>December 15, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>hepatitis A</keyword>
  <keyword>vaccine</keyword>
  <keyword>HBV and/or HCV co-infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

